Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vigonvita Life Sciences CoHKSE:02630 +5.32%8 Days Payable is 78.87 as of Dec. 2025, which is at its 10-year median of 78.87. GuruFocus rates HKSE:02630 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 926 Drug Manufacturers companies, Vigonvita Life Sciences Co ranks worse than 56.91% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co Days Payable Chart
Vigonvita Life Sciences Co Annual Data
Trend
Dec23
Dec24
Dec25
Days Payable
37.34
90.37
78.87
Vigonvita Life Sciences Co Semi-Annual Data
Dec23
Dec24
Dec25
Days Payable
37.34
90.37
78.87
HKSE:02630 vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Vigonvita Life Sciences Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vigonvita Life Sciences Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vigonvita Life Sciences Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Vigonvita Life Sciences Co's Days Payable falls into.
Vigonvita Life Sciences Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co (HKSE:02630) has a Days Payable of 78.87 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vigonvita Life Sciences Co and its competitors. This is near median its historical median of 78.87. Over the past decade, Vigonvita Life Sciences Co's Days Payable has ranged from 37.34 to 90.37. According to the industry distribution chart, Vigonvita Life Sciences Co ranks #527 out of 926 companies in the Drug Manufacturers industry, placing it in the top 56.9%.
Is Vigonvita Life Sciences Co's Days Payable too high?
Vigonvita Life Sciences Co's current Days Payable of 78.87 is near median its 10-year median of 78.87. Over the past 10 years, this metric has ranged from a low of 37.34 to a high of 90.37. The Drug Manufacturers industry median Days Payable is 90.22. Vigonvita Life Sciences Co's value of 78.87 is 12.6% below this industry median. Based on the distribution chart, Vigonvita Life Sciences Co ranks #527 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Vigonvita Life Sciences Co ranks #527 out of 926 companies for Days Payable. This places Vigonvita Life Sciences Co in the lower half of its industry. The industry median Days Payable is 90.22. Vigonvita Life Sciences Co's value of 78.87 is 12.6% below this benchmark. Historically, Vigonvita Life Sciences Co's own Days Payable has ranged from 37.34 to 90.37 over the past decade. While the company's 10-year median is 78.87 vs. the industry median of 90.22, Vigonvita Life Sciences Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vigonvita Life Sciences Co's current Days Payable of 78.87 is 12.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vigonvita Life Sciences Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vigonvita Life Sciences Co's current Days Payable is 78.87, which is near median its own 10-year median of 78.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current Days Payable of 78.87. The current Days Payable is 78.87, which is near median its 10-year median of 78.87 and 12.6% below the Drug Manufacturers industry median of 90.22. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current Days Payable is 78.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score
Get the complete analysis for HKSE:02630
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02630 has been successfully added to your 
